Systematic Review and Meta-Analysis: Clinical Utility of Continuous Performance Tests for the Identification of Attention-Deficit/Hyperactivity Disorder
Overview
Authors
Affiliations
Objective: We aimed to quantify the clinical utility of continuous performance tests (CPTs) for the diagnosis of attention-deficit/hyperactivity disorder (ADHD) compared to a clinical diagnosis in children and adolescents.
Method: Four databases (MEDLINE, PsycINFO, EMBASE, and PubMed) were screened until January 2023. Risk of bias of included results was judged with the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2). We statistically pooled the area under the curve, the sensitivity, and the specificity of 3 commonly used CPTs subscales: omission/inattention, commission/impulsivity, and total number of errors/ADHD subscales (PROSPERO registration: CRD42020168091).
Results: A total of 19 studies using commercially available CPTs were identified. Results from up to 835 control individuals and 819 cases were combined in the summary receiver operating characteristic (ROC) curve analyses (sensitivity and specificity pooling), and up to 996 cases and 1,083 control individuals in the area under the curve (AUC) analyses. Clinical utility as measured by AUCs could be considered as barely acceptable (between 0.7 and 0.8) for the most part, with the best results for the total/ADHD score, followed by omissions/inattention, and poorest for commission/impulsivity scores. A similar pattern was found when pooling sensitivity and specificity: 0.75 (95% CI = 0.66-0.82) and 0.71 (0.62-0.78) for the total/ADHD score; 0.63 (0.49-0.75) and 0.74 (0.65-0.81) for omissions; and 0.59 (0.38-0.77) and 0.66 (CI = 0.50-0.78) for commissions.
Conclusion: At the clinical level, CPTs as a stand-alone tool have only a modest to moderate ability to differentiate ADHD from non-ADHD samples. Hence, they should be used only within a more comprehensive diagnostic process.
Study Preregistration Information: A systematic review of screening tools for ADHD in children and adolescents; https://www.crd.york.ac.uk/prospero/; CRD42020168091.
Musullulu H Front Psychol. 2025; 16:1466088.
PMID: 40066184 PMC: 11891363. DOI: 10.3389/fpsyg.2025.1466088.
The ADHD Assessment Quality Assurance Standard for Children and Teenagers (CAAQAS).
Young S, Absoud M, Al-Attar Z, Ani C, Colley W, Cortese S Neuropsychiatr Dis Treat. 2024; 20:2603-2628.
PMID: 39737064 PMC: 11682937. DOI: 10.2147/NDT.S472923.
Ozaslan A, Sevri M, Iseri E, Karacan B, Cengiz M, Karacan H J Clin Med. 2024; 13(21).
PMID: 39518577 PMC: 11546344. DOI: 10.3390/jcm13216438.
Lee H, Huh H, Kim W, Lee E, Choi B, Kim B Soa Chongsonyon Chongsin Uihak. 2024; 35(4):243-249.
PMID: 39380567 PMC: 11456654. DOI: 10.5765/jkacap.240017.
Effect of ginseng and ginsenosides on attention deficit hyperactivity disorder: A systematic review.
Kim Y, Cho I, Cho S J Ginseng Res. 2024; 48(5):437-448.
PMID: 39263306 PMC: 11385392. DOI: 10.1016/j.jgr.2024.05.006.